Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06692062
Recruiting Not applicable

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

NCT06692062 · tracked via the Priya Life Science China tracker
Sponsor
Rongrong Zhou
Phase
Not applicable
Started
2024-10-01
Last updated
2024-11-18

Condition(s) studied

Thymoma and Thymic CarcinomaThymomaThymic CancerThymic Epithelial Tumor

Investigational drug(s) / intervention(s)

Hypofractionated Radiation Therapy

Hypofractionated Radiation Therapy: R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f

Study summary

The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are:

* Does Hypofractionated radiotherapy provide better results?
* Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery.

Participants will:

* Receive hypofractionated radiotherapy or conventional radiotherapy
* Visit the hospital regularly once every 12 weeks for checkups and tests

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients must provide written informed consent. 2. 18 years old ≤ age \<75 years old. 3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data. 4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ 5. ECOG performance status 0-2. 6. Expected survival time \> 1 year. 7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative. 8. Patients who are not lactating. 9. Sufficient bone marrow reserve and good function of important organs. Exclusion Criteria: 1. patients with prior thoracic radiotherapy; 2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure; 3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care 4. Patients with other malignant tumors that are not under stable control; 5. Known history of mental illness, substance abuse, alcohol or drug abuse. 6. Other conditions deemed unsuitable for enrollment by the attending physician.

Primary outcome measure(s)

  • 3-year PFS — The patients were followed up for 3 years from enrollment to disease progression or death.
    Time from enrollment to disease progression or death.

Trial sites (1)

FacilityCityRegionStatus
Xiangya Hospital, Central South University Changsha Hunan Recruiting

More Rongrong Zhou trials in China

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases Recruiting

Other trials for the same condition

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis Starting soon
Robot-assisted vs VATS for Thymoma Recruiting
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors Recruiting
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Recruiting
Molecular Analysis and Treatment Options of Thymic Malignancies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06692062 on ClinicalTrials.gov ↗ ← All trials in China